Skip to content

ADMA Biologics ADMA Lease Liability Payments - Due Year Four

Lease Liability Payments - Due Year Four at other companies

Zymeworks logo
ZymeworksZYME
$2.86M-3.4%
Abbott logo
AbbottABT
$151M+12.7%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$0-100%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's lease liability payments - due year four.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's lease liability payments - due year four?
ADMA Biologics (ADMA) reported lease liability payments - due year four of $1.9M in Q1 2026.
How has ADMA Biologics's lease liability payments - due year four changed year-over-year?
ADMA Biologics's lease liability payments - due year four decreased by 10.1% year-over-year, from $2.11M to $1.9M.
What does lease liability payments - due year four mean?
The contractual cash obligations for operating and finance leases due in the fourth year following the balance sheet date. This is part of the long-term lease maturity schedule that helps investors assess the company's future fixed cost burden. It allows for better modeling of long-term capital allocation and cash flow stability.